# The Cannabis Component CBG Shows Promise In Treating Rheumatoid Arthritis With Its … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-cannabis-component-cbg-shows-promise-in-treating-rheumatoid-arthritis-with-its/ > **Published:** 2026-05-21T00:03:36-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T21:50:43-04:00 > **Clinical Summary:** CBG preclinical study shows immunomodulation in isolated neutrophils. Clinical translation remains unknown. Evidence review for RA patients. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchHempCBGPainRheumatoid ArthritisSafetyPharmaceuticals Clinical Summary # Clinical Summary Cannabigerol (CBG), a non-intoxicating cannabinoid, demonstrated anti-inflammatory and immunomodulatory effects in preclinical studies of neutrophils relevant to rheumatoid arthritis pathophysiology. The research, published in Pharmaceuticals, suggests CBG may suppress neutrophil activation and reduce inflammatory mediator production, potentially offering a novel mechanism to address the excessive immune response characteristic of RA. While these in vitro findings are promising, the results remain preliminary and require validation through animal models and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) before CBG could be considered a therapeutic option for RA patients. Current evidence does not yet support clinical use of CBG for rheumatoid arthritis, and patients with RA should continue evidence-based conventional disease-modifying treatments. Clinicians should monitor the emerging literature on CBG and other cannabinoids in autoimmune conditions, as successful translation could eventually provide additional therapeutic options for patients with inadequate response to or intolerance of standard therapies. Dr. Caplan’s Take “What we’re seeing with CBG in the preclinical data is encouraging, but I tell my rheumatoid arthritis patients we’re still in the early stages where the science hasn’t caught up to the promise, and until we have human trials that actually measure joint inflammation and function, I can’t responsibly recommend it as a primary treatment strategy.” Clinical Perspective While cannabigerol (CBG) demonstrates [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/) on neutrophils in preclinical models, clinicians should recognize the substantial gap between in vitro findings and therapeutic efficacy in living patients with rheumatoid arthritis. The study’s isolated cell system cannot fully capture the complex interplay of immune dysregulation, systemic factors, pharmacokinetics, and [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/) that characterize RA in humans, nor does it address potential [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) on other immune populations critical to disease pathogenesis. Current evidence for cannabis and its components in RA remains limited and heterogeneous, with most [clinical data](https://cedclinic.com/uk-germany-medical-cannabis-markets-double-2025/) restricted to symptom management rather than disease modification, and dosing, formulation standardization, and long-term safety profiles remain largely undefined. Until rigorous randomized controlled trials establish efficacy and safety in actual patient populations, CBG should not be positioned as a disease-modifying agent, though clinicians may 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20Cannabis%20Component%20CBG%20Shows%20Promise%20In%20Treating%20Rheumatoid%20Arthritis%20With%20Its%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55853)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55853)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20Cannabis%20Component%20CBG%20Shows%20Promise%20In%20Treating%20Rheumatoid%20Arthritis%20With%20Its%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55853)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.marijuanamoment.net/the-cannabis-component-cbg-shows-promise-in-treating-rheumatoid-arthritis-with-its-anti-inflammatory-capacity-study-finds/](https://www.marijuanamoment.net/the-cannabis-component-cbg-shows-promise-in-treating-rheumatoid-arthritis-with-its-anti-inflammatory-capacity-study-finds/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).